Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
In microfluidic Sanger sequencing the entire thermocycling amplification of DNA fragments as well as their separation by electrophoresis is done on a single glass wafer (approximately 10 cm in diameter) thus reducing the reagent usage as well as cost. In some instances researchers have shown that they can increase the throughput of conventional sequencing through the use of microchips. Research will still need to be done in order to make this use of technology effective.
The Analyst then taunts Neo in the Matrix with bullet time by threatening to kill Trinity with a pistol, and then forces Neo to meet him in a café that he and Trinity had frequented. The crew then uses that opportunity to unplug Trinity. At the café, surrounded by riot officers, Neo distracts the Analyst while the team unplugs Trinity. They successfully unplug her, and Trinity gets her memories back and helps Neo fight the officers. Eventually, Smith fights the two, but gets away. In a final attempt to get rid of Neo and Trinity, the Analyst activates the Swarm, which forces many people to try to kill Bugs' team. The team survives, and when Neo and Trinity are cornered by police helicopters, they then decide to fly, which indeed does happen. The Analyst is defeated, and Neo and Trinity finally rekindle their romance and remake the Matrix in their own image.
==== About Huntleigh Nesbit Evans (HNE) ==== In 1969, the Flowtron Aire Ltd, the predecessor of Huntleigh Healthcare, was founded in Luton in 1975 that of the Huntleigh Group Ltd. In 1985 the company's IPO took place as a Huntleigh Technology PLC at the London Stock Exchange. In 1993 Huntleigh took over the Nesbit Evans Group and operated as HNE HUNTLEIGH NESBIT EVANS.
Sources: en.wikipedia.org
== Etymology == The name "buckwheat" comes from its tetrahedral seeds, which resemble the much larger seeds of the beech nut from the beech tree, and the fact that it is used like wheat. The word may be a translation of Middle Dutch boecweite: boec "beech" (Modern Dutch beuk; see PIE *bhago-) and weite "wheat" (Mod. Dut. tarwe, antiquated weit), or may be a native formation on the same model as the Dutch word.
Prior to trans fat regulation, hydrogenation is generally not performed fully, resulting in partially hydrogenated fat. The goal is to have some unsaturated bonds (C=C bonds) to remain to target a specific melting point and hardness. However, due to the isomerization side reaction, a significant fraction of this remaining unsaturated fat is turned into trans fat. This side reaction accounts for most of the trans fatty acids consumed in an industrialized society of the 1990s-2000s, by far. Regulation has led to some desire in tweaking for lower trans fat levels. The standard 140 kPa (20 psi) process of partial hydrogenation produces a product of about 40% trans fatty acid by weight, compared to about 17% using higher pressures of hydrogen. Blended with unhydrogenated liquid soybean oil, the high-pressure-processed oil produced margarine containing 5 to 6% trans fat. Based on 2005 U.S. labeling requirements (see below), the manufacturer could claim the product was free of trans fat. The level of trans fat may also be altered by modification of the temperature and the length of time during hydrogenation. Further regulation and consumer awareness has led to wider adoption of fully hydrogenated fats, which contain no trans fat due to an absence of double bonds. The "overshoot" in melting point and hardness could be combated by mixing in another fat, sometimes using interesterification to produce a more even blend. Plant oils rich in monounsaturated fats and saturated fats have also replaced some uses of hydrogenated fats.
Structural proteins that bind DNA are well-understood examples of non-specific DNA-protein interactions. Within chromosomes, DNA is held in complexes with structural proteins. These proteins organize the DNA into a compact structure called chromatin. In eukaryotes, this structure involves DNA binding to a complex of small basic proteins called histones, while in prokaryotes multiple types of proteins are involved. The histones form a disk-shaped complex called a nucleosome, which contains two complete turns of double-stranded DNA wrapped around its surface. These non-specific interactions are formed through basic residues in the histones, making ionic bonds to the acidic sugar-phosphate backbone of the DNA, and are thus largely independent of the base sequence. Chemical modifications of these basic amino acid residues include methylation, phosphorylation, and acetylation. These chemical changes alter the strength of the interaction between the DNA and the histones, making the DNA more or less accessible to transcription factors and changing the rate of transcription. Other non-specific DNA-binding proteins in chromatin include the high-mobility group proteins, which bind to bent or distorted DNA. These proteins are important in bending arrays of nucleosomes and arranging them into the larger structures that make up chromosomes. A distinct group of DNA-binding proteins is the DNA-binding proteins that specifically bind single-stranded DNA.
Sources: en.wikipedia.org
The report also stated that the Sinaloa Cartel was colluding with the government to destroy other cartels and protect itself and its leader, "El Chapo" Guzmán. Mexican officials have denied any corruption in the government's treatment of cartels.
In 2015, the Wildcats played in their fourth consecutive bowl game, defeating the University of New Mexico in the New Mexico Bowl. In 2017, they lost to the Purdue Boilermakers in the Foster Farms Bowl, the Wildcats 21st bowl game. Dave Heeke was named Arizona's 13th Director of Athletics in February 2017 and officially started in that role on April 1, 2017. Heeke served as Athletics Director at Central Michigan University for 11 years and as a staff member in the University of Oregon athletics department for 18 years. (Greg Byrne resigned from the post in January to accept the same role at the University of Alabama.) Rodriguez was relieved of his duties on January 2, 2018, in the wake of an internal university investigation of sexual harassment claims made by Rodriguez's former administrative assistant. After a nationwide search and much media speculation, Kevin Sumlin was hired on January 14, 2018, as the new Wildcats head football coach. Sumlin was head coach at Texas A&M University and the University of Houston. After a disappointing three-season tenure, with the Wildcats posting a 5–7 (4–5 in Pac-12) record in 2018 and a 4–8 record (2–7 in Pac-12) record in 2019, Sumlin was fired at the conclusion of the 2020 season (a truncated schedule due to the COVID-19 pandemic). After a nationwide search and much media speculation, former college and NFL coach Jedd Fisch (most recently the QB coach for the New England Patriots and a previous assistant at UCLA, Michigan, Miami and Minnesota) was chosen as the Wildcats' 32nd head football coach, as announced in December 2020.
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-{\frac {\beta (t)IS}{N}}-v(t)S,\\[6pt]&{\frac {dI}{dt}}={\frac {\beta (t)IS}{N}}-\gamma (t)I,\\[6pt]&{\frac {dR}{dt}}=\gamma (t)I,\\[6pt]&{\frac {dV}{dt}}=v(t)S,\end{aligned}}}
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.